Johnson & Johnson MedTech has received FDA approval for its device for drug-refractory paroxysmal atrial fibrillation.

Irvine: Johnson & Johnson MedTech has announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE Platform ...

The VARIPULSE™ Platform is the first and only Pulsed Field Ablation (PFA) System in the U.S. fully integrated with the CARTO™ ...

Johnson & Johnson MedTech announced today that the FDA approved its Varipulse pulsed field ablation (PFA) platform for ...

“It is basically chaotic electrical motion in the top chambers of the heart,” Dr. Alan Johnson Cardiac Physiologist for ...

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced the U.S. Food & Drug Administration (FDA) approval of the VARIPULSE™ Platform for the treatment of drug ...

Sudden cardiac death is preceded by symptoms in around ... JT-H is a consultant for Johnson and Johnson, Microport, Boston, Cytokinetics and Leo Pharma, and has received funding from John and ...

Johnson & Johnson MedTech will enter the U.S. pulsed field ablation market following an FDA green light for its Varipulse ...

J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.